147 related articles for article (PubMed ID: 31974541)
21. Multistage pH-responsive mesoporous silica nanohybrids with charge reversal and intracellular release for efficient anticancer drug delivery.
Yuan X; Peng S; Lin W; Wang J; Zhang L
J Colloid Interface Sci; 2019 Nov; 555():82-93. PubMed ID: 31377647
[TBL] [Abstract][Full Text] [Related]
22. Polymer-Coated Hollow Mesoporous Silica Nanoparticles for Triple-Responsive Drug Delivery.
Zhang Y; Ang CY; Li M; Tan SY; Qu Q; Luo Z; Zhao Y
ACS Appl Mater Interfaces; 2015 Aug; 7(32):18179-87. PubMed ID: 26221866
[TBL] [Abstract][Full Text] [Related]
23. Targeting PD-1 in CD8
Srivastava P; Paladhi A; Singh R; Srivastava DN; Singh RA; Hira SK; Manna PP
Mol Pharm; 2021 May; 18(5):2053-2065. PubMed ID: 33886324
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of STAT3 phosphorylation enhances tumoricidal effect of IL-15-activated dendritic cell against doxorubicin-resistant lymphoma and leukemia via TNF-α.
Hira SK; Mondal I; Bhattacharya D; Gupta KK; Manna PP
Int J Biochem Cell Biol; 2015 Oct; 67():1-13. PubMed ID: 26255115
[TBL] [Abstract][Full Text] [Related]
25. Multi-stimuli responsive mesoporous carbon nano-platform gated by human serum albumin for cancer thermo-chemotherapy.
Zhao Q; Wang X; Yang M; Li X; Mao Y; Guan X; Di D; Wang S
Colloids Surf B Biointerfaces; 2019 Dec; 184():110532. PubMed ID: 31590051
[TBL] [Abstract][Full Text] [Related]
26. Poly(amino acid)/ZnO/mesoporous silica nanoparticle based complex drug delivery system with a charge-reversal property for cancer therapy.
Kuang Y; Chen H; Chen Z; Wan L; Liu J; Xu Z; Chen X; Jiang B; Li C
Colloids Surf B Biointerfaces; 2019 Sep; 181():461-469. PubMed ID: 31176118
[TBL] [Abstract][Full Text] [Related]
27. Multi-stimuli responsive nanosystem modified by tumor-targeted carbon dots for chemophototherapy synergistic therapy.
Wang X; Li X; Mao Y; Wang D; Zhao Q; Wang S
J Colloid Interface Sci; 2019 Sep; 552():639-650. PubMed ID: 31173992
[TBL] [Abstract][Full Text] [Related]
28. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
29. Macroporous silica nanoparticles for delivering Bcl2-function converting peptide to treat multidrug resistant-cancer cells.
Xu W; Ge P; Niu B; Zhang X; Liu J; Xie J
J Colloid Interface Sci; 2018 Oct; 527():141-150. PubMed ID: 29787950
[TBL] [Abstract][Full Text] [Related]
30. Aerosol technique-based carbon-encapsulated hollow mesoporous silica nanoparticles for synergistic chemo-photothermal therapy.
Gautam M; Thapa RK; Poudel BK; Gupta B; Ruttala HB; Nguyen HT; Soe ZC; Ou W; Poudel K; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2019 Apr; 88():448-461. PubMed ID: 30818051
[TBL] [Abstract][Full Text] [Related]
31. Synthesis of lactoferrin mesoporous silica nanoparticles for pemetrexed/ellagic acid synergistic breast cancer therapy.
Ali OM; Bekhit AA; Khattab SN; Helmy MW; Abdel-Ghany YS; Teleb M; Elzoghby AO
Colloids Surf B Biointerfaces; 2020 Apr; 188():110824. PubMed ID: 32023511
[TBL] [Abstract][Full Text] [Related]
32. Redox-responsive mesoporous selenium delivery of doxorubicin targets MCF-7 cells and synergistically enhances its anti-tumor activity.
Zhao S; Yu Q; Pan J; Zhou Y; Cao C; Ouyang JM; Liu J
Acta Biomater; 2017 May; 54():294-306. PubMed ID: 28267598
[TBL] [Abstract][Full Text] [Related]
33. Chitosan-capped mesoporous silica nanoparticles as pH-responsive nanocarriers for controlled drug release.
Hu X; Wang Y; Peng B
Chem Asian J; 2014 Jan; 9(1):319-27. PubMed ID: 24115568
[TBL] [Abstract][Full Text] [Related]
34. A multifunctional mesoporous silica nanocomposite for targeted delivery, controlled release of doxorubicin and bioimaging.
Xie M; Shi H; Li Z; Shen H; Ma K; Li B; Shen S; Jin Y
Colloids Surf B Biointerfaces; 2013 Oct; 110():138-47. PubMed ID: 23711784
[TBL] [Abstract][Full Text] [Related]
35. Hybrid lipid-capped mesoporous silica for stimuli-responsive drug release and overcoming multidrug resistance.
Han N; Zhao Q; Wan L; Wang Y; Gao Y; Wang P; Wang Z; Zhang J; Jiang T; Wang S
ACS Appl Mater Interfaces; 2015 Feb; 7(5):3342-51. PubMed ID: 25584634
[TBL] [Abstract][Full Text] [Related]
36. Enzyme-induced and tumor-targeted drug delivery system based on multifunctional mesoporous silica nanoparticles.
Cheng YJ; Luo GF; Zhu JY; Xu XD; Zeng X; Cheng DB; Li YM; Wu Y; Zhang XZ; Zhuo RX; He F
ACS Appl Mater Interfaces; 2015 May; 7(17):9078-87. PubMed ID: 25893819
[TBL] [Abstract][Full Text] [Related]
37. DNA-Hybrid-Gated Photothermal Mesoporous Silica Nanoparticles for NIR-Responsive and Aptamer-Targeted Drug Delivery.
Zhang Y; Hou Z; Ge Y; Deng K; Liu B; Li X; Li Q; Cheng Z; Ma P; Li C; Lin J
ACS Appl Mater Interfaces; 2015 Sep; 7(37):20696-706. PubMed ID: 26325285
[TBL] [Abstract][Full Text] [Related]
38. Poly(amidoamine)-modified mesoporous silica nanoparticles as a mucoadhesive drug delivery system for potential bladder cancer therapy.
Wang B; Zhang K; Wang J; Zhao R; Zhang Q; Kong X
Colloids Surf B Biointerfaces; 2020 May; 189():110832. PubMed ID: 32070865
[TBL] [Abstract][Full Text] [Related]
39. Development of a PAMAM Dendrimer for Sustained Release of Temozolomide against Experimental Murine Lymphoma: Assessment of Therapeutic Efficacy.
Sk UH; Hira SK; Rej A; RoyMahapatra D; Manna PP
ACS Appl Bio Mater; 2021 Mar; 4(3):2628-2638. PubMed ID: 35014379
[TBL] [Abstract][Full Text] [Related]
40. ATP-Decorated Mesoporous Silica for Biomineralization of Calcium Carbonate and P2 Purinergic Receptor-Mediated Antitumor Activity against Aggressive Lymphoma.
Srivastava P; Hira SK; Srivastava DN; Singh VK; Gupta U; Singh R; Singh RA; Manna PP
ACS Appl Mater Interfaces; 2018 Feb; 10(8):6917-6929. PubMed ID: 29392934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
